Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
NCT03348904 · Incyte Corporation · PHASE3 · terminated · last registry update 2019-06-13 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.” | Open Targets' class: business administrative | Registry record, Incyte Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-02-13Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT04267848)
- 2019-12-11Phase 3 first posted: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
- 2019-01-04Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Pembrolizumab (NCT03793179)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision